Adipose Tissue-Derived Mesenchymal Stem Cells Increase Skin Allograft Survival and Inhibit Th-17 Immune Response

Citation
Larocca, Rafael Assumpção, Pedro Manoel Moraes-Vieira, Ênio José Bassi, Patrícia Semedo, Danilo Candido de Almeida, Marina Burgos da Silva, Thomas Thornley, Alvaro Pacheco-Silva, and Niels Olsen Saraiva Câmara. 2013. “Adipose Tissue-Derived Mesenchymal Stem Cells Increase Skin Allograft Survival and Inhibit Th-17 Immune Response.” PLoS ONE 8 (10): e76396. doi:10.1371/journal.pone.0076396. http://dx.doi.org/10.1371/journal.pone.0076396.

Published Version
doi:10.1371/journal.pone.0076396

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:11878966

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAAS

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Adipose Tissue-Derived Mesenchymal Stem Cells Increase Skin Allograft Survival and Inhibit Th-17 Immune Response

Rafael Assumpção Larocca1,4*, Pedro Manoel Moraes-Vieira1,5, Énio José Bassi1, Patrícia Semedo2, Danilo Candido de Almeida2, Marina Burgos da Silva1, Thomas Thornley4, Alvaro Pacheco-Silva2,3, Niels Olsen Saraiva Câmara1,2

1 Laboratory of Transplantation Immunobiology, Department of Immunology, Institute for Biomedical Sciences, University of São Paulo, São Paulo, Brazil, 2 Laboratory of Clinical and Experimental Immunology, Division of Nephrology, Federal University of São Paulo, São Paulo, Brazil, 3 Instituto Israelita de Ensino e Pesquisa Albert Einstein Hospital, Renal Transplantation Division, São Paulo, Brazil, 4 Harvard Medical School, Department of Medicine, The Transplant Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America, 5 Harvard Medical School, Department of Medicine, Division of Endocrinology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America

Abstract

Adipose tissue-derived mesenchymal stem cells (ADSC) exhibit immunosuppressive capabilities both in vitro and in vivo. Their use for therapy in the transplant field is attractive as they could render the use of immunosuppressive drugs unnecessary. The aim of this study was to investigate the effect of ADSC therapy on prolonging skin allograft survival. Animals that were treated with a single injection of donor allogeneic ADSC one day after transplantation showed an increase in donor skin graft survival by approximately one week. This improvement was associated with preserved histological morphology, an expansion of CD4+ regulatory T cells (Treg) in draining lymph nodes, as well as heightened IL-10 expression and down-regulated IL-17 expression. In vitro, ADSC inhibit naive CD4+ T cell proliferation and constrain Th-1 and Th-17 polarization. In summary, infusion of ADSC one day post-transplantation dramatically increases skin allograft survival by inhibiting the Th-17 pathogenic immune response and enhancing the protective Treg immune response. Finally, these data suggest that ADSC therapy will open new opportunities for promoting drug-free allograft survival in clinical transplantation.

Introduction

Adipose tissue-derived stem cells (ADSC) are an attractive source of multipotent mesenchymal stem cells (MSC) for use in tissue engineering and clinical applications [1]. ADSC are characterized as a heterogeneous cell population expressing the surface markers CD73, CD14, CD90 and CD105, but not the hematopoietic lineage markers CD11c, CD31, CD34, CD45, CD80 and CD86. Essentially, their plasticity and ability to differentiate into mesenchymal origin tissues such as bone, cartilage and fat are considered the hallmark criteria for ADSC classification [2,3]. Their relative abundance and easy accessibility within adult tissues make them ideal candidates for cell-based therapies. To this end, many authors have investigated their potential use to repair injured tissues [2-4].

In addition, several studies have shown that stem cells also possess immunomodulatory capabilities [5-10]. MSC inhibit T lymphocyte proliferation in mixed lymphocyte reactions (MLR) using third party stimulator cells polyclonal stimulation [11-13]. Furthermore, the administration of MSC was found to abolish graft-versus-host disease (GVHD) in human bone marrow transplantation, strongly suggesting that these cells can be used therapeutically in vivo [14]. The immunomodulation mediated by MSC requires prior activation of the MSC by immune cells through the release of proinflammatory cytokines such as IL-1α, IL-1β and IFN-γ [15,16]. This prior activation has been shown to be important since IFN-γ receptor-1-deficient MSC are unable to exert any immunosuppressive effects [16]. However, once activated these MSC can release several soluble factors, such as indoleamine 2,3-deoxigenase (IDO), prostaglandin E2 (PGE2), inducible nitric-oxide synthase (iNOS) and IL-6 that have immunomodulatory effects on other cell types [12,13,17]. PGE2 was shown to have a negative effect on the maturation of dendritic cells, driving these cells instead to produce immunoregulatory IL-10 [18]. Similarly, IL-6 was reported to inhibit the maturation of dendritic cells through the down-regulation of costimulatory molecules such as CD40, and thereby block their ability to prime T cells [19,20].
Moreover, MSC-derived IL-6 was shown to prolong neutrophil and lymphocyte survival [21, 22]. Overall, these data show the capacity of MSC to inhibit the immune response by restraining dendritic cell maturation and inducing a concomitant loss of function in NK, B and T cell compartments [23, 24]. More than that, MSC can induce the expansion of regulatory CD4\(^+\) T cells in the periphery [25, 26] while also inhibiting Th-17 cell generation [27, 28]. Accordingly, the use of ADSC has been widespread since they can be harvested easily via liposuction and then expanded in vitro. These ADSC can suppress T cell immune responses in vivo in the GVHD model [29] as well as in experimental models of autoimmune diseases [25, 30, 31]. However, the use of ADSC to induce transplant tolerance remains untested. Herein, we sought to study the therapeutic potential of allogeneic ADSC in orchestrating immunoregulation and prolonging skin allograft survival in a mouse model.

**Materials and Methods**

**Animals**

CBA/J (H-2\(^b\)) and C57BL/6 (H-2\(^b\)) mice were obtained from our Isogenic Breeding Unit (Immunology Department, Institute for Biomedical Science, University of São Paulo – Brazil). All animals were used at 8–10 weeks of age. All protocols were conducted in adherence to the Brazilian Committee for Experimental Animals and were approved by the institutional ethics committee on animal use of the University of São Paulo (Protocol # 010, page 42 issue 2).

**Antibodies**

Anti-CD3, anti-CD4 and anti-CD25 were purchased from BD Pharmingen; anti-CD11c, anti-CD31, anti-CD34, anti-CD40, anti-CD44, anti-CD45, anti-CD73, anti-CD80 and anti-CD86 were purchased from BioLegend; anti-Foxp3 was purchased from eBioscience.

**Skin Transplantation**

Full-thickness skin grafts 1 to 2 cm in diameter were obtained from the tail-skin CBA/J donor mice and transplanted onto the back of C57BL/6 recipient mice [32]. Graft rejection was defined as the first day on which the entire graft was necrotic [32].

**Isolation and Characterization of ADSC**

ADSC were collected from the epididymal fat of CBA/J mice and washed with phosphate-buffered saline (PBS). The fat was finely minced and digested with collagenase IV (Sigma) in a 37°C shaking water bath for 30 min. Then, the cell suspension was centrifuged and the cell pellet was resuspended in DMEM-low-glucose (Invitrogen, EUA) supplemented with 10% fetal bovine serum (FBS, Gibco) and penicillin/streptomycin (Invitrogen). Cells were plated and incubated for 10 days under adipogenic culture condition and colored orange lipid vesicles could be observed (400×). Osteogenic differentiation: cells were stained with (Von Kossa) after 28 days under osteogenic culture condition and colored calcium deposition is observed. (D) Chondrogenic differentiation: cells were stained with (Safranin O) after 21 days under chondrogenic conditions and intense red glycosaminoglycan staining was observed. Magnification 200×.

doi:10.1371/journal.pone.0076396.g001

Figure 1. Isolation and in vitro characterization of ADSC. These cells were obtained after collagenase digestion (type V) of abdominal fat tissue from CBA/J mice and cultured in DMEM low-glucose supplemented with 10% FBS. Adherent cells were used in experiments through passage 8. Flow cytometry analyses from passage 6 are illustrated in panel (A). FSC by SSC indicates a homogeneous population in size and granularity. These cells were positive for CD44 and CD73 and negative for CD31, CD34, CD45, CD80 and CD86. More then $1 \times 10^6$ events were acquired and the frequency of positive cells was determined using FlowJo. In vitro, these cells displayed the potential to differentiate into adipogenic, chondrogenic and osteogenic cells. ADSC were cultured in control (-) or differentiation (+) culture media, as described in the Methods. (B) Adipogenic differentiation: cells were stained with (Oil Red O) after 10 days under adipogenic culture condition and colored orange lipid vesicles could be observed (400×). (C) Osteogenic differentiation: cells were stained with (Von Kossa) after 28 days under osteogenic culture condition and colored calcium deposition is observed. (D) Chondrogenic differentiation: cells were stained with (Safranin O) after 21 days under chondrogenic conditions and intense red glycosaminoglycan staining was observed. Magnification 200×.
ADSC and Bone Marrow Mononuclear Cell Adoptive Transfers

On day +1 after skin transplantation, C57BL/6 mice were divided into three experimental groups: animals that received a single injection of 0.2 ml of PBS i.p. (Allo); animals that received $5 \times 10^5$ CBA-ADSC i.p. (Allo-ADSC) or (B6-ADSC) or (Balb/c-ADSC); animals that received $5 \times 10^5$ bone-marrow mononuclear cells i.p. (BMMC). In all experiments, we used 5 mice per group. The experiments were repeated three times.

Cell Staining and Flow Cytometry

Cells obtained from the axillary lymph node were resuspended in FACS buffer (PBS with 2% FBS) and stained for flow cytometry analysis. To block Fc receptor-mediated binding of antibodies, mononuclear leukocytes were resuspended in FACS buffer with hamster anti-mouse CD16/32, clone 2.4G2 (Fc Block™, BD Bioscience) for 20 minutes. These cells were then washed, placed on ice for 30 minutes, and stained with fluorochrome-conjugated antibodies. Cells were washed twice in buffer and reserved for analysis. Intracellular staining for Foxp3 was performed on lymph node cells according to the manufacturer’s procedure (eBioscience). Intracellular staining for IFN-γ and IL-17 was performed on CD4+ T cells after activation with Leukocyte Activation Cocktail (BD Biosciences) and following cell permeabilization and fixation with the BD Cytofix/Cytoperm Fixation/Permeabilization Solution Kit (BD Biosciences) using the manufacturer’s protocol. For proliferation analyses, cells were stained with 5 μM CFSE using the manufacturer’s protocol. For cell acquisition, we used the BD FACSCanto II flow-cytometer (BD Biosciences). Data analysis for these experiments was performed using FlowJo software (Tree Star).

Histology

The histological analysis of the skin graft was performed by staining 5 μm sections of paraffin embedded tissues with hematoxylin and eosin (HE) or Sirius red.

Real-Time PCR

Skin and lymph node samples were initially snap-frozen in liquid nitrogen. Total RNA was isolated using the TRIzol Reagent (Invitrogen) according to manufacturer’s protocol. RNA concentrations were determined using NanoDrop (Thermo Scientific). First-strand cDNAs were synthesized using MML-V reverse transcriptase (Promega). Real-time PCR was performed using TaqMan PCR assays (Applied Biosystems) for the following genes of interest: IL-2 (Mm00434255_g1), IL-6 (Mm00446190_m1), IL-10 (Mm00475156_m1), IFN-γ (Mm00446968_m1), IL-17 (Mm00439619_m1), Foxp3 (Mm00475156_m1), HPRT (Mm00446968_m1), IFN-γ (Mm00801778_m1) and TGF-β (Mm03434553_m1). Quantitative real-time PCR was performed via ABI PRISM 7300 Sequence...
Detection System (Applied Biosystems). Transcript levels were normalized to the expression of HPRT. Analyses were performed with the Sequence Detection Software 1.9 (SDS).

MLR-based Suppression Assay
Stimulator mature DCs (5 \times 10^4 cells per well) from CBA/J mice were co-cultured with CFSE labeled naive CD4^+ T cells (1.5 \times 10^5 cells per well) isolated from draining lymph nodes of C57BL/6 mice using a CD4^+ T cell positive selection kit (Miltenyi Biotechnology) according the manufacturer’s protocol. Cultures were performed with or without the addition of increasing concentrations of ADSC in a 96-well U-bottom plate. For the contact dependent assay, cells were incubated in a 96 transwell plate. Cells were incubated at 37°C for 96 hours. Cells were analyzed by flow cytometry. CD4^+ T cell proliferation and DC activation marker expression were analyzed by FlowJo.

Supernatant Cytokine Measurements by Bioplex®
A Bio-Plex mouse Plex cytokine assay kit (Bio-Rad laboratories) was used in conjunction with the Bio-Plex system array reader according to the manufacturer’s directions. The specific cytokines (IL-4, IL-10 and IFN-γ) were quantified. Standard curves for each of the analyzed cytokines were included in each run and sample concentrations were calculated using Bio-Plex Manager software version 4.0. Standard curves ranged from 32,000 to 1.95 pg/mL.

Statistics
Data were analyzed using Prism5 (GraphPad Software Inc.), and the results were expressed as mean ± SEM. In the analysis, comparisons were made using the Mann Whitney t test. Survival curves were estimated by the Kaplan-Meier method and compared with a Log Rank test. P<0.05 was considered significant.

Results
Characterization of Adipose-derived Mesenchymal Stem Cells
MSC can suppress immune responses both in vitro and in vivo [9,25]. However, it is unknown whether this immunosuppressive capacity can be exploited for therapeutic advantage through the induction of tolerance to transplanted allografts. We therefore tested the hypothesis that MSC can generate a tolerogenic microenvironment imparting prolonged skin allograft survival. To address this hypothesis, we derived in vitro MSC from epididymal adipose tissue, which exhibit greater immunosuppressive capacity as compared to MSCs from bone marrow [35]. After three passages, the ADSC were collected and characterized by flow cytometry for CD11c, CD31, CD34, CD44, CD45, CD73, CD80 and CD86. As expected, the cells expressed CD44 and CD73 but not other markers (Figure 1A). Moreover, these ADSC exhibited characteristics of pluripotency as evidenced by their differentiation into adipocytes, chondrocytes as well as osteocytes under different culture conditions (Figure 1B).
To address the question of whether ADSC can prolong allogeneic skin graft survival, wild type C57BL/6 mice were transplanted with fully MHC-mismatch tail skin from CBA/J mice followed by the passive transfer of ADSC derived from donor-matched CBA/J mice (allo-ADSC), host-matched C57Bl/6 (B6-ADSC), or third-party Balb/c (Balb/c-ADSC). In the untreated control group that received a single intraperitoneal injection of PBS one day after transplantation, the median survival time (MST) of transplanted skin grafts was 12 days. Strikingly, a single injection of $5 \times 10^5$ donor-matched allo-ADSC one day after transplantation prolonged skin graft survival to an MST of 17 days. In contrast, the transfer of $5 \times 10^5$ B6-ADSC or Balb/c-ADSC did not show improved graft survival with an MST of 12.5 and 11 days, respectively (Figure 2A).

Consistent with prolonged skin allograft survival, allo-ADSC treated animals presented a healthier skin morphology with maintenance of the collagen orientation (Figure 2B), higher neutrophil infiltration (Figure 2C), and lower necrosis (Figure 2D) when compared to untreated control mice 10 days post-transplantation. These histological improvements were accompanied by an elevated expression of vascular endothelial growth factor (VEGF) as assessed by quantitative PCR (qRT-PCR) (Figure 2E) and an increase in the frequency of CD4$^+$Foxp3$^+$ regulatory T cells as determined by flow cytometry in the draining lymph node 3 days post-transplantation.

ADSC Administration Prolongs Allogeneic Skin Graft Survival

To address the question of whether ADSC can prolong allogeneic skin graft survival, wild type C57BL/6 mice were transplanted with fully MHC-mismatch tail skin from CBA/J mice followed by the passive transfer of ADSC derived from donor-matched CBA/J mice (allo-ADSC), host-matched C57Bl/6 (B6-ADSC), or third-party Balb/c (Balb/c-ADSC). In the untreated control group that received a single intraperitoneal injection of PBS one day after transplantation, the median survival time (MST) of transplanted skin grafts was 12 days. Strikingly, a single injection of $5 \times 10^5$ donor-matched allo-ADSC one day after transplantation prolonged skin graft survival to an MST of 17 days. In contrast, the transfer of $5 \times 10^5$ B6-ADSC or Balb/c-ADSC did not show improved graft survival with an MST of 12.5 and 11 days, respectively (Figure 2A). Moreover, transfer of donor-matched mononuclear cells from bone marrow, which has a low fraction of MSC, failed to increase graft survival as compared to the untreated control (MST = 12 days, Figure 2A).

Consistent with prolonged skin allograft survival, allo-ADSC treated animals presented a healthier skin morphology with maintenance of the collagen orientation (Figure 2B), higher neutrophil infiltration (Figure 2C), and lower necrosis (Figure 2D) when compared to untreated control mice 10 days post-transplantation. These histological improvements were accompanied by an elevated expression of vascular endothelial growth factor (VEGF) as assessed by quantitative PCR (qRT-PCR) (Figure 2E) and an increase in the frequency of CD4$^+$Foxp3$^+$ regulatory T cells as determined by flow cytometry in the draining lymph node 3 days post-transplantation.

ADSC Treatment Inhibits IL-2 and IFN-γ Expression in the Graft at the Time of Rejection

Given that skin transplants survived longer in allo-ADSC treated mice, we hypothesized that ADSC treatment would lead to
a decrease in the expression of T cell effector cytokines such as IL-2 and IFN-γ. Moreover, this treatment could increase in the expression of the immunoregulatory molecules such as Foxp3, and favor the expansion of CD4+ Foxp3+ T cells. To test this hypothesis, we initially quantified the mRNA levels of IL-2, IFN-γ and Foxp3 in the transplanted skin graft and draining lymph nodes of allo-ADSC treated and control mice on the day of each individual animal rejection. Interestingly, we found higher expression of IL-2 and IFN-γ in the skin graft obtained from the untreated group as opposed to the allo-ADSC treated group (Figure 2G). This increase in IL-2 and IFN-γ expression in the skin graft was inverted in the draining lymph nodes. However, we did not observe any difference in Foxp3 expression between the two groups (Figure 2G).

**ADSC Treatment Increases the Expression of IL-6, IL-10, IFN-γ, and Foxp3 in the Lymph Node, but Reduces IL-17 Expression in the Skin Graft**

To closely examine the expression of molecules related to allograft tolerance and rejection, we harvested lymph nodes and skin grafts early (day 3) and preceding allograft rejection (day 10) post-transplantation. Interestingly, Foxp3 expression was higher in the draining lymph nodes of allo-ADSC treated mice than control mice on day 3 (Figure 2G), corroborating our earlier findings by flow cytometry (Figure 2F). We also observed higher IL-6 expression in the allo-ADSC treated group on day 3, which is not entirely unexpected due to ADSC’s known ability to secrete high levels of IL-6 [22] (Figure 3A). Interestingly, we observed higher levels of IL-10 and IFN-γ in draining lymph nodes from allo-ADSC treated mice as compared to control mice on day 10 post-transplantation (Figure 3A). IFN-γ is often correlated as an effector cytokine produced by T cells during graft destruction, but it is also known that IFN-γ may have a suppressive function by inducing effector cell apoptosis [36]. Furthermore, it is also known that immunosuppression mediated by MSC depends on prior activation by proinflammatory cytokines [15,16,24]. ADSC can facilitate the production of IL-10 by other cell subtypes such as Treg, monocytes and dendritic cells [18,37]. Regardless, untreated animals expressed higher levels of IL-17 in the skin graft on days 3 and 10 as compared to allo-ADSC treated animals (Figure 3B).

**ADSC Suppress Alloreactive Effector CD4+ T cell Proliferation and Differentiation in vitro**

To test the ability of the ADSC to suppress effector CD4+ T cells in a mixed leukocyte reaction (MLR), we performed an in vitro suppression assay. Splenic CD11c+ dendritic cells from CBA/J mice were co-cultured with purified C57BL/6 CD4+ T cells labeled with CFSE. After 5 days of culture, CD4+ T cells proliferated in response to allogeneic dendritic cells as measured by CFSE dilution (Figure 4A upper panel). The addition of
increasing concentrations of CBA/J ADSC inhibited the proliferation of these CD4+ T cells in a dose-dependent manner (Figure 4A), reducing the frequency of proliferating responder cells by up to 20%. When we co-cultured CD4+ T cells with two different concentrations of ADSC alone, no proliferation was observed (Figure 4A lower panel). Even though the difference in the frequency of cells (represented by the gating) is not dramatic, we decided to evaluate the number of cells in each generation. Strikingly, when we analyzed the sixth and seventh generations, the number of cells that had proliferated in response to the allogeneic stimulus (DC+CD4) was 8-fold higher in comparison to the groups co-cultured with ADSC (Figure 4B). Moreover, when we measured the replication index, which determines the fold-expansion of only responding cells, we observed a more than 2-fold difference in proliferation (Figure 4C). Interestingly, this inhibition was not associated with a substantial increase in IL-10 production (Figure 4D). Additionally, this inhibition of proliferation was accompanied by a complete inhibition of effector T cell cytokine production, as demonstrated by an absolute abrogation of IFN-γ and IL-17 expression, the prototypic cytokines of Th-1 and Th-17 cells, respectively (Figure 4E).

ADSC Suppress DC Costimulatory Molecules in vitro, in a Contact Dependent Manner

To test whether the suppression that ADSC exerted on the CD4+ T cell proliferation was due to an indirect effect that ADSC had on DC, and to determine whether this effect was due to soluble factors or cell contact dependent, we performed an MLR using a transwell system. We observed that CD11c+ cells cultured with contact had lower levels of costimulatory molecules, such as CD11c, CD40 and CD80, as compared with CD11c+ cells cultured that were separated from ADSC by a cytokine-permeable transwell membrane (Figure 5A and B). We did not observe any difference in CD86 expression (Figure 5A).

Discussion

Transplantation remains the best treatment option to correct certain types of organ failure and tissue damage (i.e. kidney, heart, lung, etc.). However, the long-term use of globally immunosuppressive drugs to prevent rejection carries with it some serious risks, including infection and cancer due to their lack of target specificity, as well as graft loss due to their toxicity [38]. Thus, identifying safe methodologies to induce donor-specific allograft survival is a top priority. One of the most attractive targets for such therapy is Treg, which have emerged as pivotal immunoregulators in the establishment of allograft tolerance [39–41]. While Treg improve graft survival in several experimental models, their low frequency under homeostatic conditions remains a roadblock to their therapeutic use. Consequently, finding strategies to expand Treg is essential for clinical success.

Herein, we exploited the immunoregulatory nature of ADSC to expand Treg and prolong skin graft survival. Similar to bone marrow-derived mesenchymal stem cells, ADSC found in adipose tissue possess extensive proliferative capacity and the ability to differentiate into multiple cell lineages [42,43]. Due to the relative abundance of abdominal fat in normal individuals and the ability to isolate MSC after liposuction, we chose to use abdominal fat as the mesenchymal stem cell source [42]. Data from the literature shows that ADSC are better than bone marrow derived MSC and possess more potent immunomodulatory effects on DC [44,45].

Strikingly, when allo-ADSC were administrated, they significantly increased allograft survival compared with the untreated animals, although this did not result in permanent allograft tolerance. Moreover, transfer of ADSC from either a syngeneic donor or a third party donor (Balb/c) did not improve allograft survival, demonstrating that the prolongation of allograft survival is donor antigen specific. This is similar to results from previous studies showing that a donor specific transfusion (DST) into recipients can prolong allograft survival in both humans [46] and mice. Prolongation is enhanced when accompanied by anti-CD40L treatment [47].

Our data illustrate the potential of ADSC to suppress immune responses across a full MHC barrier. Furthermore, these data are in contrast to the results we obtained through the injection of mononuclear bone marrow cells, which we observed as having no beneficial effect on allograft survival as compared to the untreated controls. We presume that the low frequency of mesenchymal stem cells in the bone marrow makes it necessary to first expand or purify these cells in vitro prior to injection.

The fact that we do not see a long-term prolongation of the skin graft survival with ADSC might be due to ADSC rejection. Moreover, a recent study suggests that allogeneic MSC can be recognized by the innate and adaptive immune systems [48]. However, more detailed studies will be needed to clarify the precise mechanisms involved. We also believe that the immunogenicity of skin is an obstacle to achieving tolerance. Numerous models have demonstrated that it is difficult to generate permanent allograft tolerance to skin transplants [49]. In fact, it has been noted during whole hand transplantation that the skin was the first tissue to be rejected [50,51].

Consistent with improved allograft survival, we observed a better histological morphology and preservation of collagen orientation with ADSC as compared to control treatment. Additionally, neutrophil infiltration was higher in ADSC treated mice as compared to the untreated group. While there are studies showing that neutrophils might contribute to allograft rejection [52–54], Larocca et al., have also shown the importance of neutrophil infiltration for graft acceptance in a skin transplant model [55]. Neutrophils produce vascular-endothelial grow factor (VEGF), an important growth factor needed for neovascularization and tissue repair [56]. Consistent with this, we observed increased VEGF expression in ADSC treated animals.

Additionally, we observed that the number of Treg in the draining lymph nodes from ADSC treated animals 72 hours after transplantation was increased as compared to untreated animals. We believe that this effect could be through direct expansion of the Treg pool, as it was already shown by our group that Treg proliferate in vitro in the presence of ADSC [25]. However, this profile was not maintained past day 10, when the number was equivalent between both groups. The hypothesis that these cells migrated to the graft was disproven when we failed to observe any difference in Foxp3 expression in the graft.

Next, we observed that the expression of IL-2 and IFN-γ transcripts was higher in the draining lymph node of the ADSC treated group, but lower in the graft of the untreated group. We believe that the ADSC migrated to the draining lymph nodes as our group has shown that ADSC injected into non-obese diabetic (NOD) mice migrate to the pancreatic lymph node (PLN), thus preventing insulinitis and new onset diabetes [25]. Moreover, while IL-2 is an important growth factor for effector T cells, it is also an important growth factor for Treg. In vitro IL-2 and IFN-γ has been shown to be important in triggering MSCs to induce tolerance [57]. And, while it is well established that IFN-γ has an important role during the alloimmune response against the graft [58], it is also known that it can generate skin graft tolerance by activation of STAT-1 in a Treg population that is dependent on IFN-γ [59]. Furthermore, MSC-mediated immunosuppression is dependent
on IFN-γ since MSC cells from IFN-γ receptor-1 knockout mice lack immunosuppressive capacity in vitro [16]. Moreover, skin allograft acceptance has been shown to be dependent on the presence of IFN-γ, as the addition of an anti-IFN-γ mAb or use of an IFN-γ knockout mouse was associated with prompt graft rejection [32].

We also observed that the expression of IL-6 was elevated in the ADSC treated group as compared to the untreated control group. While IL-6 has been shown to inhibit Treg, MSC-derived IL-6 also inhibits DC maturation, decreasing their capacity to prime T cells. IL-6 also delays apoptosis in neutrophils, providing one possible explanation for why we see an increase in neutrophil infiltration [19,21,22]. Thus, we hypothesize that these immature dendritic cells could be a source of the IL-10 observed in our studies.

Finally, we observed that ADSC suppressed CD4+ T cell proliferation and differentiation in vitro as well as expression of costimulatory molecules by DC (mainly CD40), a process that was contact dependent. The fact that we still observed some T cell proliferation in the presence of ADSC, but complete abrogation of cytokine production, is consistent with a previous publication showing that, in the absence of CD40 signaling, CD4+ T cells retain the capacity to proliferate but are unable to develop effector characteristics [62]. Thus, ADSC decreased the number of lineage-committed Th-1/Th-17 cells as evidenced by a decrease in the production of IFN-γ and IL-17 by CD4+ T cells, which is in agreement with the literature [63].

In conclusion, we found that ADSC inhibited IL-17 production and expanded Treg in vivo thereby generating improved allograft survival in a skin transplant model. Prolonged transplant survival was associated with higher expression of IL-6, IL-10 and IFN-γ. As ADSC are plentiful in patient adipose tissue, the isolation and deployment of an ADSC therapy is an attractive methodology for the clinical prolongation of allograft survival.

Acknowledgments

We appreciate the technical support from Bernardo Paulo Albe for the preparation of the histological slides and Dr. Rosana Rosa Miranda Corrêa for the pathological analysis of the skin grafts. We also appreciate the collaboration of Cintia Raquel Bombardieri, Giancarlo Trentim and Mark Justin Lampioni.

Author Contributions

Conceived and designed the experiments: RAL NOSC. Performed the experiments: RAL PMMV EJB PS DCA MBdS. Analyzed the data: RAL PMMV EJB DCA MBdS TT NOSC. Contributed reagents/materials/analysis tools: APS NOSC. Wrote the paper: RAL TT NOSC.

References

1. Heydarkhan-Hagvall S, Schenke-Layland K, Yang QJ, Heydarkhan S, Xu Y, et al. (2008) Human adipose stem cells: a potential cell source for cardiovascular tissue engineering. Cells Tissues Organs 187: 263-274.
2. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, et al. (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147.
3. Sekiya I, Larson BL, Smith JR, Pochampally R, Cui JG, et al. (2005) Bone marrow adipose tissue is a source of mesenchymal stromal cells with cord blood hematopoietic potential. Blood 105: 2214-2219.
4. Kawada H, Fujita J, Kinjo K, Matsuzaki Y, Tsuma M, et al. (2004) A human adipose-derived stromal cell line expressing CD34 and HLA-DR. Stem Cells 22: 398-405.
5. Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F, et al. (2005) Bone marrow adipose tissue is a source of mesenchymal stromal cells with cord blood hematopoietic potential. Blood 105: 2214-2219.
6. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC (2003) Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75: 389-397.
7. Di Nicola M, Carlo-Stella C, Magini M, Milanesi M, Longoni PD, et al. (2002) Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or non-specific mitogenic stimuli. Blood 99: 3383-3383.
8. Le Blanc K (2005) Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy 7: 485-489.
9. Le Blanc K, Tammik I, Sundberg B, Haynesworth SE, Ringden O (2003) Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 57: 11-20.
10. Potjan JA, Aivi H, Punzon NM, Harrison JS, Rameshwar P (2003) Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol 171: 3436-3444.
11. Bryth S, Bosovs V, Mevarach D, Liebergall M, Gazit Z, et al. (2005) Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105: 2214-2219.
12. Meisel R, Zibert A, Laryea M, Gehel U, Dauheren W, et al. (2004) Human bone marrow stromal cells inhibit alloreactive T-cell responses by inducing 2,3-dioxoglycide-generated tryptophan degradation. Blood 103: 4619-4621.
13. Aggarwal S, Pittenger MF (2005) Human mesenchymal stem cells mediate alloregenic immune cell responses. Blood 105: 1815-1822.
14. Le Blanc K, Rasmusson I, Sundberg B, Goetherstrom C, Hassan M, et al. (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363: 1439-1441.
15. Krampera M, Cosmi I, Angeli R, Pasini A, Liotta F, et al. (2006) Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24: 386-398.
16. Ren G, Zhang L, Xiao X, Xu G, Zhang Y, et al. (2008) Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2: 141-150.
17. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, et al. (2007) Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 109: 228-234.
18. Neneth K, Leelahavanichkul A, Yuan PS, Meyer B, Parmelee A, et al. (2009) Bone marrow stromal cell-attenuated sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 15: 42-49.
19. Djuoud F, Charbonnier LM, Brailli C, Louis-Flence P, Bony C, et al. (2007) Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 25: 2025-2032.
20. Zhang ZG, He QY, Liu XM, Tang XY, Chen LZ (2006) Effect of Interleukin-17 on neutrophil apoptosis. Beijing Da Xue Xue Bao 36: 305-309.
21. Raffaglino L, Bianchi G, Bertolotto M, Montecucco F, Basa A, et al. (2008) Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells 26: 151-162.
22. Xu G, Zhang Y, Zeng L, Ren G, Shi Y (2007) The role of IL-6 in inhibition of lymphocyte apoptosis by mesenchymal stem cells. Biochem Biophys Res Commun 361: 745-750.
23. Corcione A, Benvenuto F, Ferreti E, Giunti D, Cappiello V, et al. (2006) Human mesenchymal stem cells modulate Be-2 cell functions. Blood 107: 367-372.
24. Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, et al. (2008) Human leukocyte antigen-G3 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25+ high FOXP3+ regulatory T cells. Stem Cells 26: 212-222.
25. Bassi EJ, Moraes-Vieira PM, Moreira-Sa CS, Almeida DC, Vieira LM, et al. (2012) Immune regulatory properties of allogeneic adipose-derived mesenchymal stem cells in the treatment of experimental autoimmune diabetes. Diabetes 61: 2534-2545.
26. English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, et al. (2009) Cell contact, prostaglandin E2(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(high) forkhead box P3+ regulatory T cells. Clin Exp Immunol 156: 149-160.
27. Ghannam S, Pene J, Torcy-Moquet G, Jorgensen C, Yssel H. (2010) Mesenchymal stem cells inhibit Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol 185: 302–312.

28. Luz-Crawford P, Noel D, Fernandez X, Khoury M, Figueroa F, et al. (2012) Mesenchymal Stem Cells Repress Th17 Molecular Program through the PD-1 Pathway. PLoS One 7: e45272.

29. Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, et al. (2008) IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 38: 1743–1755.

30. Fiorena P, Jurewicz M, Augello A, Vergani A, Dada S, et al. (2009) Immuno-modulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol 183: 983–1004.

31. Constantin G, Marconi S, Rossi B, Angiari S, Calderan L, et al. (2009) Adipose-tissue-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells 27: 2624–2635.

32. Markes TG, Phillips NE, Gordon EJ, Nostell RJ, Shultz LD, et al. (1996) Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+), T cells, interferon-gamma, and CTLA4. J Clin Invest 101: 2466–2475.

33. Bunnell BA, Faust M, Gagliardi C, Patel B, Ripoll C. (2008) Adipose-derived stem cells: isolation, expansion and differentiation. Methods 45: 115–120.

34. Cho KS, Park HK, Park HY, Jung JS, Jeon SG, et al. (2009) IFATS collection: Immuno-modulatory effects of adipose tissue-derived stem cells in an allergic rhinitis mouse model. Stem Cells 27: 259–265.

35. Niemeyer P, Kornacker M, Melhorn E, Seckinger A, Voheer J, et al. (2007) Comparison of immunological properties of bone marrowstromal cells and adipose tissue-derived stem cells before and after osteogenic differentiation in vitro. Tissue Eng 13: 111–121.

36. Asavaroengchai W, Wang H, Wang S, Wang L, Brunson R, et al. (2007) An essential role for IFN-gamma in regulation of alloreactive CD8 T cells following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 13: 46–53.

37. Zhang W, Ge W, Li C, You S, Liao L, et al. (2009) Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev 18: 263–271.

38. Lopez MM, Valenzuela JE, Alvarez FC, Lopez-Alvarzar MR, Cecilia GS, et al. (2006) Long-term problems related to immunosuppression. Transpl Immunol 17: 31–35.

39. Kang SM, Tang Q, Blustone JA (2007) CD4+CD25+ regulatory T cells in transplantation: progress, challenges and prospects. Am J Transplant 7: 1453–1467.

40. Wood KJ, Bashell A, Hester J (2012) Regulatory immune cells in transplantation. Nat Rev Immunol 12: 417–430.

41. Wang J, Huang H, Zhao Y, Wei Y, Wang Y, et al. (2006) Foamy+CD25+CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 212: 8–27.

42. Zik PA, Zhu M, Adipose P, De Ugarte DA, Huang JL, et al. (2002) Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 13: 4279–4285.

43. Katz AJ, Tholpady A, Tholpady SS, Shang H, Ogle RC (2005) Cell surface and transcriptional characterization of human adipose-derived adherent stromal (hADAS) cells. Stem Cells 23: 412–423.

44. Ivanova-Todorova E, Bochev I, Mordueva M, Dimitrov R, Bukavek D, et al. (2009) Adipose tissue-derived mesenchymal stem cells are more potent suppressors of dendritic cell differentiation compared to bone marrow-derived mesenchymal stem cells. Immunol Lett 126: 37–42.

45. Zhu Y, Liu T, Song K, Fan X, Ma X, et al. (2008) Adipose-derived stem cell: a better stem cell than BMSC. Cell Biochem Funct 26: 664–673.

46. Brennan DC, Mohanakumar T, Flye MW (1995) Donor-specific transfusion and donor bone marrow infusion in renal transplantation tolerance: a review of efficacy and mechanisms. Am J Kidney Dis 26: 701–715.

47. Parker DC, Greiner DL, Phillips NE, Appel MC, Steele AW, et al. (1995) Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci U S A 92: 9560–9564.

48. Griffin MD, Ryan AE, Alagesan S, Lohan P, Treacy O, et al. (2013) Ami-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far? Immunol Cell Biol 91: 40–51.

49. Wood KJ, Bashell A, Hester J (2012) Regulatory immune cells in transplantation. Nat Rev Immunol 12: 417–430.

50. Klimczak A, Siemionow M (2007) Immune responses in transplantation: application to composite tissue allograft. Semin Plastic Surg 21: 226–233.

51. Murray JE (1971) Organ transplantation (skin, kidney, heart) and the plastic surgeon. Plast Reconstr Surg 47: 425–431.

52. Hirayama S, Shirashi T, Shirakusa T, Higuchi T, Miller EJ (2006) Prevention of neutrophil migration ameliorates rat lung allograft rejection. Mol Med 12: 208–213.

53. Surpin M, Buoncurose S, Le Moine A, Flamand V, Goldman M, et al. (2005) The role of neutrophils during allograft rejection. Nephrol Ther 1: 161–166.

54. Morita K, Miura M, Paolone DR, Engerman TM, Kapoor A, et al. (2001) Early chemokine cascades in murine cardiac grafts regulate T cell recruitment and progression of acute allograft rejection. J Immunol 167: 2979–2984.

55. Larocca R, Marguti I, Cabrera W, Ribeiro OG, Rizzo LV, et al. (2008) Maximal inflammatory response benefits syngeneic skin graft acceptance. Inflamm Res 57: 171–177.

56. Nuzawa H, Chiu C, Hanahan D (2006) Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A 103: 12493–12498.

57. Renner P, Eggenhofer E, Roennauer A, Popp FC, Steinmann JP, et al. (2009) Mesenchymal stem cells require a sufficient, ongoing immune response to exert their immunosuppressive function. Transplant Proc 41: 2607–2611.

58. Hidalgo LG, Halloran PF (2002) Role of IFN-gamma in allograft rejection. Crit Rev Immunol 22: 317–349.

59. Feng G, Gao W, Stout TB, Oskia M, Francis RS, et al. (2006) Exogenous IFN-gamma ex vivo shapes the alloreactive T-cell repertoire by inhibition of Th17 responses and generation of functional Foxp3+ regulatory T cells. Eur J Immunol 36: 2512–2527.

60. Betelli E, Carrier Y, Gao W, Korn T, Strom TB, et al. (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235–238.

61. Peters A, Lee Y, Kachroo VK (2011) The many faces of Th17 cells. Curr Opin Immunol 23: 762–766.

62. MacLeod M, Kwakkenbos MJ, Crawford A, Brown S, Stockinger B, et al. (2006) CD4 memory T cells survive and proliferate but fail to differentiate in the absence of CD40. J Exp Med 203: 897–906.

63. English K, Wood KJ (2013) Mesenchymal stem cells in transplantation rejection and tolerance. Cold Spring Harb Perspect Med 3: a015560.